Carole Nuechterlein

Head, Roche Venture Fund

Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.

Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals.  Due to her background in M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals.

She currently serves as a director at Arch Oncology, CiVi, Millendo, Mission Therapeutics, Lumos, Lysosomal Therapeutics, Inc, Second Genome and Vivet. She was formerly a director at Allakos and AveXis. She also led the investments on Alios, Ambit, Ambrx, Conatus, Envoy, Nereus and Pharmasset.

She has a BA from Valparaiso University and a JD from University of Michigan.

More information on the Roche Venture Fund can be found at www.venturefund.roche.com.